Adverum Biotechnologies, Inc. announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience in ophthalmology, most recently as chief research and development officer at Allergan. Prior to Allergan, Dr. Nicholson served on the executive committee of Bayer CropScience as executive vice president of research and development and chief technology officer; as senior vice
president of licensing and knowledge management at Merck; as senior vice president at Schering-Plough, responsible for global project management and drug safety; and in multiple positions of increasing responsibility including ultimately as executive vice president of research and development at Organon. Dr. Nicholson currently serves as the non-executive chair of the boards of directors of Exscientia and Wild Bioscience, a member of the board of directors of Volastra, the lead independent director of Actinium Pharmaceuticals, and an operational partner at Gilde Healthcare. Dr. Nicholson
received his B.S. from the University of Manchester and his Ph.D. from the University of Wales.